Plasma fenfluramine levels, weight loss, and side effects.

Area of Science:

• Pharmacology
• Endocrinology
• Obesity Research

Background:

• Refractory obesity presents a significant challenge in clinical practice.
• Fenfluramine, a serotonin-releasing agent, has been investigated for its potential in weight management.

Purpose of the Study:

• To evaluate the efficacy of fenfluramine in promoting weight loss in women with refractory obesity.
• To investigate the relationship between plasma fenfluramine concentrations, anorexia, side effects, and weight loss.

Main Methods:

• A 20-week open-label study involving 50 women with refractory obesity.
• Regular monitoring of weight change, drug dosage, anorexia, side effects, and plasma fenfluramine/norfenfluramine levels.
• Dose escalation to a maximum of 160 mg/day.

Main Results:

• A significant correlation was observed between weight loss and plasma fenfluramine/norfenfluramine concentrations.
• Sustained anorexia was also significantly related to weight loss.
• Women with higher mean plateau plasma fenfluramine concentrations (>200 ng/ml) achieved greater mean weight loss (8.8 kg) compared to those with lower concentrations (<100 ng/ml; 2.1 kg).
• Plasma fenfluramine levels did not correlate with anorexia severity or most side effects, except for dream disturbance.

Conclusions:

• Plasma fenfluramine and norfenfluramine concentrations are key indicators of weight loss efficacy in refractory obesity.
• Stepwise dose titration of fenfluramine is advised to balance therapeutic effects and potential side effects.